ICMJE DISCLOSURE FORM

Date: 20 June, 2021
Your Name: Zixian Jin
Manuscript Title: Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
Manuscript number (if known): ____ATM-21-2804

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
|   | **Time frame: Since the initial planning of the work**                                          |                                                                                  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | _X_ None                                                                        |
|   | **No time limit for this item.**                                                                  |                                                                                  |
|   | **Time frame: past 36 months**                                                                  |                                                                                  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                        | _X_ None                                                                        |
| 3 | Royalties or licenses                                                                            | _X_ None                                                                        |
| 4 | Consulting fees                                                                                 | _X_ None                                                                        |
|   | Description                                                                 | Answer |
|---|----------------------------------------------------------------------------|--------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | __X__ None |
| 6 | Payment for expert testimony                                                | __X__ None |
| 7 | Support for attending meetings and/or travel                                 | __X__ None |
| 8 | Patents planned, issued or pending                                          | __X__ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           | __X__ None |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | __X__ None |
| 11| Stock or stock options                                                      | __X__ None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | __X__ None |
| 13| Other financial or non-financial interests                                   | __X__ None |

Please summarize the above conflict of interest in the following box:

None.

Please place an “X” next to the following statement to indicate your agreement:

__X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 20 June, 2021
Your Name: Jianfei Shen
Manuscript Title: Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
Manuscript number (if known): ____ATM-21-2804

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| # | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|
| **Time frame: Since the initial planning of the work** |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br>No time limit for this item. | _X_ None |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _X_ None |
| 3 | Royalties or licenses | _X_ None |
| 4 | Consulting fees | _X_ None |
| **Time frame: past 36 months** |

---

1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)

No time limit for this item.

_X_ None
|   |   | __X__ None |
|---|---|------------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events |   |
| 6 | Payment for expert testimony |   |
| 7 | Support for attending meetings and/or travel |   |
| 8 | Patents planned, issued or pending |   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid |   |
| 11 | Stock or stock options |   |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services |   |
| 13 | Other financial or non-financial interests |   |

Please summarize the above conflict of interest in the following box:

None.

Please place an “X” next to the following statement to indicate your agreement:

__X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 20 June, 2021
Your Name: Chunguo Wang
Manuscript Title: Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
Manuscript number (if known): ____ATM-21-2804

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** |                                                                                                         |                                                                                                                   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | _X_ None                                                                                                           |
|   | **No time limit for this item.**                                                            |                                                                                                                   |
| **Time frame: past 36 months**                                                                 |                                                                                                                   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                   | _X_ None                                                                                                           |
| 3 | Royalties or licenses                                                                      | _X_ None                                                                                                           |
| 4 | Consulting fees                                                                           | _X_ None                                                                                                           |
|   | Description                                                                                           | Response |
|---|-------------------------------------------------------------------------------------------------------|----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | __X__None |
| 6 | Payment for expert testimony                                                                          | __X__None |
| 7 | Support for attending meetings and/or travel                                                           | __X__None |
| 8 | Patents planned, issued or pending                                                                       | __X__None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                                       | __X__None |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid      | __X__None |
| 11| Stock or stock options                                                                                   | __X__None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services                        | __X__None |
| 13| Other financial or non-financial interests                                                               | __X__None |

Please summarize the above conflict of interest in the following box:

None.

Please place an “X” next to the following statement to indicate your agreement:

__X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 20 June, 2021
Your Name: Dong Chen
Manuscript Title: Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
Manuscript number (if known): ___ATM-21-2804

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
|   | **Time frame: Since the initial planning of the work**                                         |                                                                                   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | ___X__ None                                                                       |
|   |                                                                                               |                                                                                   |
|   | **Time frame: past 36 months**                                                                 |                                                                                   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                      | ___X__ None                                                                       |
| 3 | Royalties or licenses                                                                         | ___X__ None                                                                       |
| 4 | Consulting fees                                                                               | ___X__ None                                                                       |
|   |   |   |
|---|---|---|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _X_ None |
| 6 | Payment for expert testimony | _X_ None |
| 7 | Support for attending meetings and/or travel | _X_ None |
| 8 | Patents planned, issued or pending | _X_ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _X_ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _X_ None |
| 11 | Stock or stock options | _X_ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _X_ None |
| 13 | Other financial or non-financial interests | _X_ None |

**Please summarize the above conflict of interest in the following box:**

None.

**Please place an “X” next to the following statement to indicate your agreement:**

_ _X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 20 June, 2021
Your Name: Bo Zhang
Manuscript Title: Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
Manuscript number (if known): ____ATM-21-2804

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
|   | **Time frame: Since the initial planning of the work**                                         |                                                                                  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | __X__None                                                                       |
|   | **No time limit for this item.**                                                                |                                                                                  |
|   | **Time frame: past 36 months**                                                                  |                                                                                  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                       | __X__None                                                                       |
| 3 | Royalties or licenses                                                                          | __X__None                                                                       |
| 4 | Consulting fees                                                                                | __X__None                                                                       |
|   | Description                                                                                     | Answer |
|---|-------------------------------------------------------------------------------------------------|--------|
|5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | X None |
|6 | Payment for expert testimony                                                                     | X None |
|7 | Support for attending meetings and/or travel                                                      | X None |
|8 | Patents planned, issued or pending                                                                | X None |
|9 | Participation on a Data Safety Monitoring Board or Advisory Board                                 | X None |
|10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | X None |
|11| Stock or stock options                                                                           | X None |
|12| Receipt of equipment, materials, drugs, medical writing, gifts or other services                  | X None |
|13| Other financial or non-financial interests                                                         | X None |

**Please summarize the above conflict of interest in the following box:**

None.

**Please place an “X” next to the following statement to indicate your agreement:**

__X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 20 June, 2021
Your Name: Jian Zhang
Manuscript Title: Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
Manuscript number (if known): ___ATM-21-2804 __________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
|   | **Time frame: Since the initial planning of the work**                                       |                                                                                  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | __X__ None                                                                        |
|   | **No time limit for this item.**                                                             |                                                                                  |
|   | **Time frame: past 36 months**                                                              |                                                                                  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                   | __X__ None                                                                        |
| 3 | Royalties or licenses                                                                       | __X__ None                                                                        |
| 4 | Consulting fees                                                                             | __X__ None                                                                        |
|   |   |   |
|---|---|---|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _X_ None |
| 6 | Payment for expert testimony | _X_ None |
| 7 | Support for attending meetings and/or travel | _X_ None |
| 8 | Patents planned, issued or pending | _X_ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _X_ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _X_ None |
| 11 | Stock or stock options | _X_ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _X_ None |
| 13 | Other financial or non-financial interests | _X_ None |

**Please summarize the above conflict of interest in the following box:**

None.

**Please place an “X” next to the following statement to indicate your agreement:**

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: May 9, 2021
Your Name: Jaffer A. Ajani
Manuscript Title: Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
Manuscript number (if known): ATM-21-2804

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.). No time limit for this item. | _X_ None                                                                           |

Time frame: Since the initial planning of the work

|   | Grants or contracts from any entity (if not indicated in item #1 above). | Merck | Research grants received by my institution |
|---|-------------------------------------------------------------------------|-------|--------------------------------------------|
| 2 | Royalties or licenses                                                  | _X_ None |
| 3 | Consulting fees                                                        | Merck | Ad hoc advisory board member (fees received) |

Time frame: past 36 months
|   | Description                                                                 | Answer |
|---|------------------------------------------------------------------------------|--------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | X None |
| 6 | Payment for expert testimony | X None |
| 7 | Support for attending meetings and/or travel | X None |
| 8 | Patents planned, issued or pending | X None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | X None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | X None |
| 11 | Stock or stock options | X None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X None |
| 13 | Other financial or non-financial interests | X None |

Please summarize the above conflict of interest in the following box:

Dr. Ajani serves as an Ad Hoc advisory member to Merck (paid relationship), and his institution receives research grant from Merck.

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 28 April 2021
Your Name: Jaafar Bennouna
Manuscript Title: Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
Manuscript number (if known): ATM-21-2804

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | **X** None |
|   | **Time frame: Since the initial planning of the work** |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Astra-Zeneca |
| 3 | Royalties or licenses | **X** None |
| 4 | Consulting fees | **X** None |
|   | **Time frame: past 36 months** |
|   |   |   |
|---|---|---|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | BMS, Astra-Zeneca, Bayer, Servier, Roche, AMGEN, Daiichi, MSD |
| 6 | Payment for expert testimony | _X_ None |
| 7 | Support for attending meetings and/or travel | _X_ None |
| 8 | Patents planned, issued or pending | _X_ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | AstraZeneca, Bristol-Myers Squibb, F. Hoffmann–La Roche Ltd, MSD, Novartis, AMGEN, Servier |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _X_ None |
| 11 | Stock or stock options | _X_ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _X_ None |
| 13 | Other financial or non-financial interests | _X_ None |

Please summarize the above conflict of interest in the following box:

Dr. Bennouna reports Grants for research from Astra-Zeneca, and is on the advisory board with honorarium in AstraZeneca, Bristol-Myers Squibb, F. Hoffmann–La Roche Ltd, MSD, Novartis, AMGEN, Servier, participates in the educational events with honorarium of BMS, Astra-Zeneca, Bayer, Servier, Roche, AMGEN, Daiichi, MSD.

Please place an “X” next to the following statement to indicate your agreement:

_ X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: May 25, 2021
Your Name: Joseph Chao
Manuscript Title: Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
Manuscript number (if known): ATM-21-2804

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | **X** None |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | |
| **3** | Royalties or licenses | **X** None |
| **4** | Consulting fees | Merck, Amgen, Ono Pharmaceuticals, Foundation Medicine, |
AstraZeneca

|   |                                                                                   |
|---|-----------------------------------------------------------------------------------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript    |
|   | writing or educational events                                                     |
|   | __X__ None                                                                        |
| 6 | Payment for expert testimony                                                      |
|   | __X__ None                                                                        |
| 7 | Support for attending meetings and/or travel                                      |
|   | __X__ None                                                                        |
| 8 | Patents planned, issued or pending                                                |
|   | __X__ None                                                                        |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                 |
|   | Macrogenics, Daiichi-Sankyo, Bristol Myers Squibb, Astellas, Turning Point       |
|   | Therapeutics, Yiviva                                                              |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group,|
|   | paid or unpaid                                                                    |
|   | __X__ None                                                                        |
| 11| Stock or stock options                                                            |
|   | __X__ None                                                                        |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services  |
|   | __X__ None                                                                        |
| 13| Other financial or non-financial interests                                         |
|   | __X__ None                                                                        |

Please summarize the above conflict of interest in the following box:

Dr. Chao reports grants and personal fees from Merck, personal fees from Amgen, Macrogenics, Ono Pharmaceuticals, Foundation Medicine, Daiichi-Sankyo, Bristol Myers Squibb, AstraZeneca, Astellas, Turning Point Therapeutics and Yiviva, outside the submitted work.

Please place an “X” next to the following statement to indicate your agreement:

__X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: May 25, 2021
Your Name: Harry H. Yoon
Manuscript Title: Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
Manuscript number (if known): ____ATM-21-2804 ____________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | _X_ None |
|   | **No time limit for this item.**                                                |                                                                                           |
|   | **Time frame: Since the initial planning of the work**                         |                                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).       | _X_ None |
| 3 | Royalties or licenses                                                           | _X_ None |
| 4 | Consulting fees                                                                 | _X_ None |
|   | **Time frame: past 36 months**                                                 |                                                                                           |
|   | Description                                                                 | Answer |
|---|-----------------------------------------------------------------------------|--------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _X_ None |
| 6 | Payment for expert testimony                                               | _X_ None |
| 7 | Support for attending meetings and/or travel                               | _X_ None |
| 8 | Patents planned, issued or pending                                         | _X_ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           | _X_ None |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _X_ None |
|11 | Stock or stock options                                                      | _X_ None |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _X_ None |
|13 | Other financial or non-financial interests                                  | _X_ None |

Please summarize the above conflict of interest in the following box:

None.

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
Date: 20 June, 2021
Your Name: Hongyu Zhu
Manuscript Title: Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
Manuscript number (if known): ATM-21-2804

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
|   | **Time frame: Since the initial planning of the work**                                         |                                                                                  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | __X__ None                                                                      |
|   |                                                                                                 |                                                                                  |
|   | **Time frame: past 36 months**                                                                  |                                                                                  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                        | __X__ None                                                                      |
| 3 | Royalties or licenses                                                                          | __X__ None                                                                      |
| 4 | Consulting fees                                                                                | __X__ None                                                                      |
|   |   |   |
|---|---|---|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | \_X\_ None |
| 6 | Payment for expert testimony | \_X\_ None |
| 7 | Support for attending meetings and/or travel | \_X\_ None |
| 8 | Patents planned, issued or pending | \_X\_ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | \_X\_ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | \_X\_ None |
| 11 | Stock or stock options | \_X\_ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | \_X\_ None |
| 13 | Other financial or non-financial interests | \_X\_ None |

Please summarize the above conflict of interest in the following box:

None.

Please place an “X” next to the following statement to indicate your agreement:

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 20 June, 2021
Your Name: Yuhang Ruan
Manuscript Title: Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
Manuscript number (if known): ____ATM-21-2804

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | __X__ None                                                                      |
|   | **Time frame: Since the initial planning of the work**                                           |                                                                                 |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                       | __X__ None                                                                      |
| 3 | Royalties or licenses                                                                          | __X__ None                                                                      |
| 4 | Consulting fees                                                                                | __X__ None                                                                      |
|   | **Time frame: past 36 months**                                                                 |                                                                                 |
|   |   |   |
|---|---|---|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | __X__ None |
| 6 | Payment for expert testimony | __X__ None |
| 7 | Support for attending meetings and/or travel | __X__ None |
| 8 | Patents planned, issued or pending | __X__ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | __X__ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | __X__ None |
| 11 | Stock or stock options | __X__ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | __X__ None |
| 13 | Other financial or non-financial interests | __X__ None |

Please summarize the above conflict of interest in the following box:

None.

Please place an “X” next to the following statement to indicate your agreement:

__X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 20 June, 2021
Your Name: Chengchu Zhu
Manuscript Title: Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
Manuscript number (if known): ____ATM-21-2804 __________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
|   | **Time frame: Since the initial planning of the work**                                                                                                                                     |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | __X__ None                                                                                                                                 |
|   | **No time limit for this item.**                                                                                                                                                           |
|   | **Time frame: past 36 months**                                                                                                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                                                  | __X__ None                                                                                                                                 |
| 3 | Royalties or licenses                                                                                                                                                                       | __X__ None                                                                                                                                 |
| 4 | Consulting fees                                                                                                                                                                            | __X__ None                                                                                                                                 |


|   |                                                                                           | ___X__ None |
|---|-------------------------------------------------------------------------------------------|-------------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ___X__ None |
| 6 | Payment for expert testimony                                                               | ___X__ None |
| 7 | Support for attending meetings and/or travel                                                | ___X__ None |
| 8 | Patents planned, issued or pending                                                          | ___X__ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                           | ___X__ None |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ___X__ None |
|11 | Stock or stock options                                                                      | ___X__ None |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services            | ___X__ None |
|13 | Other financial or non-financial interests                                                  | ___X__ None |

Please summarize the above conflict of interest in the following box:

None.

Please place an “X” next to the following statement to indicate your agreement:

___X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 20 June, 2021
Your Name: Anyi Xu
Manuscript Title: Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
Manuscript number (if known): ____ATM-21-2804

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | __X__ None |
| | **No time limit for this item.** | |
| **Time frame: past 36 months** | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | __X__ None |
| 3 | Royalties or licenses | __X__ None |
| 4 | Consulting fees | __X__ None |
|   | Description                                                                 | X | None |
|---|----------------------------------------------------------------------------|----|------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | X | None |
| 6 | Payment for expert testimony                                                | X | None |
| 7 | Support for attending meetings and/or travel                                | X | None |
| 8 | Patents planned, issued or pending                                          | X | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           | X | None |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | X | None |
| 11| Stock or stock options                                                      | X | None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | X | None |
| 13| Other financial or non-financial interests                                  | X | None |

Please summarize the above conflict of interest in the following box:

None.

Please place an "X" next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.